Business, energy, technology, markets and global industry news from Business News Today

obesity treatment

PharmaDeviceNews obesity treatment
Pharma & Biotech

Apotex Sevmia challenges Wegovy as generic GLP-1 competition begins in Canada

Read how Apotex’s Sevmia approval could reshape Canada’s semaglutide market, and why dosing, pricing and reimbursement still matter.

Read More
Representative image of obesity treatment research. Kalohexis’ 710GO data highlights growing interest in dual MC3R and MC4R activation as the next frontier in weight loss drug development.
Pharma & Biotech

Kalohexis 710GO data puts melanocortin obesity drugs back in the metabolic spotlight

GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.

Read More
Representative image: Novo Nordisk’s Wegovy pill launch in the U.S. obesity drug market is illustrated through unbranded tablets, prescription growth data and healthcare market signals, reflecting rising demand for oral GLP-1 weight-loss treatments.
Pharma & Biotech

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.

Read More
Medical Devices & Diagnostics

Can Anaxiom’s AVOS device open a new minimally invasive route in obesity treatment?

Find out how Anaxiom’s AVOS obesity device could reshape minimally invasive weight-loss treatment after early human results.

Read More
Pharma & Biotech

How Novo Nordisk may be lowering one of the biggest operational barriers in GLP-1 distribution

Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.

Read More
Pharma & Biotech

Can Currax and Peek make oral obesity treatment easier to access for self-funded employers?

Currax expands Contrave access through PeekDirect. Read what this could mean for obesity drug pricing, employers, and non-GLP-1 treatment adoption.

Read More
Representative image of an oral obesity treatment concept illustrating how Eli Lilly and Company’s Foundayo approval could widen access to GLP-1 weight loss therapy and reshape the next phase of the obesity drug market.
Pharma & Biotech

Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected

Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.

Read More
Zepbound KwikPen arrives on Ro as Eli Lilly tightens control over obesity drug distribution
Medical Devices & Diagnostics

Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing

Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.

Read More
Pharma & Biotech

What the Hims & Hers Health, Inc. and Novo Nordisk collaboration reveals about the future of obesity drug commercialization

Explore how Hims & Hers and Novo Nordisk are expanding GLP-1 access and what it means for obesity care, pricing, and regulation.

Read More
Pharma & Biotech

Why TIXiMED’s TIX100 data highlights a growing therapeutic gap after GLP-1 weight-loss treatment

TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.

Read More